Literature DB >> 15728485

The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing.

Tatiana N Golovina1, Susan E Morrison, Laurence C Eisenlohr.   

Abstract

Evidence suggests that most epitopes presented by MHC class I molecules are derived from those newly synthesized proteins that are defective due to errors during manufacture. We examined epitope production from model cytosolic and exocytic proteins modified in various ways. Substrates containing a degradation targeting sequence demonstrated very rapid turnover and enhanced epitope production, as was the case for substrate retargeted from endoplasmic reticulum to cytosol. For less radical alterations, including point mutation and deletion and elimination of glycosylation sites, despite detectable changes in folding, half-life was only moderately decreased and there were no significant increases in epitope production. Puromycin, which causes premature termination of protein synthesis, also had no impact upon epitope production. It appears that most defective proteins are not rapidly dispensed with and the targeting of most nascent proteins for Ag processing is not tied to quality control.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728485     DOI: 10.4049/jimmunol.174.5.2763

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Substrate-induced protein stabilization reveals a predominant contribution from mature proteins to peptides presented on MHC class I.

Authors:  Jeff D Colbert; Diego J Farfán-Arribas; Kenneth L Rock
Journal:  J Immunol       Date:  2013-10-30       Impact factor: 5.422

2.  Hydrophobicity as a driver of MHC class I antigen processing.

Authors:  Lan Huang; Matthew C Kuhls; Laurence C Eisenlohr
Journal:  EMBO J       Date:  2011-03-04       Impact factor: 11.598

Review 3.  Re-examining class-I presentation and the DRiP hypothesis.

Authors:  Kenneth L Rock; Diego J Farfán-Arribas; Jeff D Colbert; Alfred L Goldberg
Journal:  Trends Immunol       Date:  2014-02-21       Impact factor: 16.687

4.  Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.

Authors:  Gabriela L Cosma; Jenna L Lobby; Elizabeth J Fay; Nicholas A Siciliano; Ryan A Langlois; Laurence C Eisenlohr
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-27       Impact factor: 11.205

5.  Cutting Edge: Selective role of ubiquitin in MHC class I antigen presentation.

Authors:  Lan Huang; Julie M Marvin; Nia Tatsis; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2011-01-14       Impact factor: 5.422

Review 6.  Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands.

Authors:  Brian P Dolan; Jack R Bennink; Jonathan W Yewdell
Journal:  Cell Mol Life Sci       Date:  2011-03-17       Impact factor: 9.261

7.  Stressed Out - Therapeutic Implications of ER Stress Related Cancer Research.

Authors:  Randal Riha; Pooja Gupta-Saraf; Payel Bhanja; Samyak Badkul; Subhrajit Saha
Journal:  Oncomedicine       Date:  2017-09-27

8.  Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I.

Authors:  Ender Simsek; Gomathinayagam Sinnathamby; Timothy M Block; Yuanjie Liu; Ramila Philip; Anand S Mehta; Pamela A Norton
Journal:  Virology       Date:  2008-12-16       Impact factor: 3.616

9.  Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.

Authors:  Adam E Snook; Benjamin J Stafford; Peng Li; Gene Tan; Lan Huang; Ruth Birbe; Stephanie Schulz; Matthias J Schnell; Mathew Thakur; Jay L Rothstein; Laurence C Eisenlohr; Scott A Waldman
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

10.  N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase.

Authors:  Marina Ostankovitch; Michelle Altrich-Vanlith; Valentina Robila; Victor H Engelhard
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.